Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized …
C Paul, J Cather, M Gooderham… - British Journal of …, 2015 - academic.oup.com
Background Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized …
C Paul, J Cather, M Gooderham… - British Journal of …, 2015 - Wiley Online Library
Background Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
[PDF][PDF] Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III …
C Paul, J Cather, M Gooderham, Y Poulin… - Br J …, 2015 - cyberleninka.org
Objectives ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for
moderate-to-severe plaque psoriasis. Methods This phase III, double-blind, placebo …
moderate-to-severe plaque psoriasis. Methods This phase III, double-blind, placebo …
[PDF][PDF] Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III …
C Paul, J Cather, M Gooderham, Y Poulin… - British Journal of …, 2015 - academia.edu
Objectives ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for
moderate-to-severe plaque psoriasis. Methods This phase III, double-blind, placebo …
moderate-to-severe plaque psoriasis. Methods This phase III, double-blind, placebo …
[引用][C] Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III …
C Paul, J Cather, M Gooderham, Y Poulin… - British Journal of …, 2015 - cir.nii.ac.jp
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with
moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial …
moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial …
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized …
C Paul, J Cather, M Gooderham… - British Journal of …, 2015 - portalrecerca.uab.cat
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with
moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized controlled trial …
moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized controlled trial …
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized …
C Paul, J Cather, M Gooderham, Y Poulin… - British Journal of …, 2015 - infona.pl
Background Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
[PDF][PDF] Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III …
C Paul, J Cather, M Gooderham, Y Poulin, U Mrowietz… - Br J Dermatol, 2015 - core.ac.uk
Objectives ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for
moderate-to-severe plaque psoriasis. Methods This phase III, double-blind, placebo …
moderate-to-severe plaque psoriasis. Methods This phase III, double-blind, placebo …
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized …
C Paul, J Cather, M Gooderham… - The British journal …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized …
C Paul, J Cather, M Gooderham, Y Poulin… - BRITISH JOURNAL OF …, 2015 - iris.univr.it
BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune
responses associated with psoriasis. OBJECTIVES: ESTEEM 2 evaluated the efficacy and …
responses associated with psoriasis. OBJECTIVES: ESTEEM 2 evaluated the efficacy and …